Finding the Therapeutic Sweet Spot: Using Naturally Occurring Human Variants to Inform Drug Design.
From the Department of Clinical Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (J.R.B.); and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (J.R.B.); and Department of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, Ontario, Canada (R.A.H.).
John R
JR
Burnett
From the Department of Clinical Biochemistry, PathWest Laboratory Medicine, Royal Perth Hospital, Perth, Western Australia, Australia (J.R.B.); and School of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia, Australia (J.R.B.); and Department of Medicine and Robarts Research Institute, Schulich School of Medicine, Western University, London, Ontario, Canada (R.A.H.). hegele@robarts.ca.
Robert A
RA
Hegele
D000012:Abetalipoproteinemia / Q000235:genetics*; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism*; D006801:Humans; D008297:Male
D002352:Carrier Proteins
Editorials; apolipoproteins B; cholesterol, LDL; genetics; humans; mutation